Efficacy and Safety Evaluation of Lumateperone in Acute Manic Episodes of Bipolar I Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial

The primary objective of this study is to evaluate the **efficacy** of lumateperone 42 mg, administered once daily, compared to placebo in the acute treatment of patients experiencing manic episodes or manic episodes with mixed features associated with **Bipolar I Disorder**. This is measured by the change from baseline to the end of Week 3 in the Young Mania Rating Scale (YMRS) total score. The clinical relevance of this objective lies in its potential to provide a new therapeutic option for managing acute manic episodes in patients with Bipolar I Disorder, which can significantly impact patient outcomes and quality of life.

Secondary objectives include assessing the efficacy of lumateperone 42 mg compared to placebo in the same patient population, as measured by the change from baseline to the end of Week 3 in the Clinical Global Impression-Severity (CGI-S) score. This secondary measure provides additional insights into the overall clinical impression of the severity of the disorder, further supporting the primary efficacy findings.

The clinical trial involves a total of **286 participants** diagnosed with **Bipolar I Disorder (Bipolar Mania)**. The study population includes both male and female inpatients aged between 18 and 75 years. Participants were selected based on their ability to provide written informed consent and their diagnosis, confirmed by a trained and sponsor-approved rater, meeting the criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, Text Revision. The trial population is characterized by individuals experiencing a current episode of mania or mania with mixed features, with or without psychotic symptoms, and who have been hospitalized voluntarily or admitted to an inpatient unit due to the current manic episode. The study does not specify particular lifestyle considerations such as diet or physical activity. The trial includes a vulnerable population, ensuring a comprehensive assessment of the efficacy of lumateperone 42 mg in the acute treatment of manic episodes associated with bipolar I disorder.

The clinical trial is designed to evaluate the **efficacy** and safety of **lumateperone** in the acute treatment of patients experiencing manic episodes or manic episodes with mixed features associated with **Bipolar I Disorder**. This is a multicenter, randomized, double-blind, placebo-controlled study. Participants will be randomly assigned to receive either lumateperone 42 mg or a placebo, administered orally once daily. The trial is expected to last for a total of three weeks, with the primary endpoint being the change from baseline to the end of Week 3 in the Young Mania Rating Scale (YMRS) total score. Secondary endpoints include the change from baseline to the end of Week 3 in the Clinical Global Impressions-Severity (CGI-S) score.

The study will commence with an inclusion (screening) visit, where potential participants will be assessed for eligibility based on specific criteria, including age, diagnosis, and severity of symptoms. Eligible participants will provide written informed consent and must be hospitalized voluntarily or admitted to an inpatient unit with a primary diagnosis of mania. Following the screening, participants will undergo a baseline visit to confirm eligibility and establish baseline measurements. Throughout the trial, participants will attend regular follow-up visits to monitor their progress and ensure safety. The end-of-study visit will occur at the conclusion of the three-week treatment period, where final assessments will be conducted to evaluate the treatment's efficacy and safety.

Participant involvement is expected to last for the duration of the three-week treatment period. However, conditions that may lead to early termination from the study include withdrawal of consent, adverse events, or any other medical reasons deemed necessary by the investigator. The trial is scheduled to begin recruitment on September 16, 2024, and is estimated to conclude by February 5, 2026. This study is categorized as a Phase III trial, focusing on a drug not currently authorized for the population involved in the planned clinical trial.

The clinical trial involves the administration of **lumateperone**, a chemical small molecule, as the experimental medication. Lumateperone is provided in the form of capsules, with each capsule containing 42 mg of the active substance. The route of administration is oral, and the medication is to be taken once daily. The maximum treatment period for lumateperone is three weeks. The primary objective of the study is to evaluate the efficacy of lumateperone in the acute treatment of patients experiencing manic episodes or manic episodes with mixed features associated with **Bipolar I Disorder**. The efficacy is measured by the change in the Young Mania Rating Scale (YMRS) total score from baseline to the end of Week 3.

The study also includes a **placebo** group, where participants receive placebo capsules that are identical in appearance to the lumateperone capsules but do not contain the active substance. The placebo is administered orally, once daily, for the same duration of three weeks. The use of placebo allows for a double-blind, placebo-controlled study design, ensuring that neither the participants nor the investigators know which treatment the participants are receiving, thereby minimizing bias in the assessment of the treatment's efficacy and safety.

The efficacy of lumateperone in the treatment of **bipolar I disorder** with manic episodes or manic episodes with mixed features will be assessed in this clinical trial. The primary efficacy endpoint is the change from baseline to the end of Week 3 in the Young Mania Rating Scale (YMRS) total score. This scale is a widely used, validated tool for measuring the severity of manic episodes. The secondary efficacy endpoint is the change from baseline to the end of Week 3 in the Clinical Global Impressions-Severity (CGI-S) score, which provides an overall clinician-determined summary measure of the patient's current state. Efficacy assessments will be conducted at baseline and at the end of Week 3, with data collected and analyzed to determine the effectiveness of lumateperone 42 mg administered once daily compared to placebo. The trial is designed as a multicenter, randomized, double-blind, placebo-controlled study, ensuring rigorous evaluation of the treatment's efficacy.